

1 **Structural distortions induced by Kinase Inhibiting RNase Attenuator**
2 **(KIRA) compounds prevent the formation of face-to-face dimers of**
3 **Inositol Requiring Enzyme 1 α .**

4

5 **Short title: KIRA compounds disrupt IRE1 face-to-face dimer formation.**

6

7 Antonio Carlesso¹, Chetan Chintha², Adrienne M. Gorman², Afshin Samali² and Leif A.
8 Eriksson^{1*}

9 ¹Department of Chemistry and Molecular Biology, University of Gothenburg, 405 30 Göteborg,
10 Sweden

11 ²Apoptosis Research Centre, National University of Ireland Galway, Galway, Ireland.

12

13

14 ORCID ID:

15 A.C.: 0000-0002-8318-7784

16 C.C.: 0000-0002-0105-8066

17 A.M.G.: 0000-0002-6068-0058

18 A.S.: 0000-0002-8610-8375

19 L.A.E.: 0000-0001-5654-3109

20

21 Correspondence

22 *Leif A. Eriksson, Department of Chemistry and Molecular Biology,

23 University of Gothenburg, 405 30 Göteborg, Sweden.

24 Email: leif.eriksson@chem.gu.se

25 Phone: +46 317869117

26

27

28

29

30

31

32 **Abstract**

33 Inositol-Requiring Enzyme 1 α (IRE1 α) is a transmembrane dual kinase/ribonuclease protein
34 involved in propagation of the unfolded protein response (UPR). IRE1 α is currently explored
35 as a potential drug target due to growing evidence of its role in variety of disease conditions.
36 Upon activation, IRE1 cleaves X-box Binding Protein 1 (XBP1) mRNA through its RNase domain.
37 Small molecules targeting the kinase site are known to either increase or decrease RNase
38 activity, but the allosteric relationship between the kinase and RNase domains of IRE1 α is
39 poorly understood. Subsets of IRE1 kinase inhibitors (known as “KIRA” compounds) bind to
40 the ATP-binding site and allosterically impede the RNase activity. KIRA compounds are able to
41 regulate the RNase activity by stabilizing monomeric form of IRE1 α .

42 In the present work, computational analysis, protein-protein and protein-ligand docking
43 studies, and molecular dynamics simulations were applied to different IRE1 dimer systems to
44 provide structural insights into the perturbation of IRE1 dimers by small molecules kinase
45 inhibitors that regulate the RNase activity. By analyzing structural deviations, energetic
46 components and number of hydrogen bonds in the interface region, we propose that the KIRA
47 inhibitors act at an early stage of IRE1 activation by interfering with IRE1 face-to-face dimer
48 formation, thus disabling the activation of the RNase domain. The work sheds light on the
49 mechanism of action of KIRA compounds and may assist in development of further
50 compounds in e.g. cancer therapeutics. The work also provides information on the sequence
51 of events and protein-protein interactions initiating the unfolded protein response.

52

53

54 **Keywords:** IRE1, KIRA, dimer formation, unfolded protein response, protein-protein docking,
55 molecular dynamics simulations

56

57

58 **Non-technical Summary**

59 The unfolded protein response is a protective feedback mechanism whereby cells regulate
60 high levels of misfolded proteins in the endoplasmic reticulum. Due to its significance in cell
61 survival, the UPR has become an interesting target in cancer therapy. A key pathway of the
62 UPR is initiated by the activation of inositol requiring enzyme 1 α (IRE1 α), which must first
63 dimerise in order to mediate the stress signal. Different inhibitors have been proposed in
64 order to block the UPR at the level of IRE1 α . We here unveil, through detailed computational
65 studies, the mode of action of a set of IRE1 α inhibitors targeting the kinase domain, which in
66 turn helps us to further understand the mechanism of activation and progression of the UPR.

67

68

69

70 1. Introduction

71 The accumulation of misfolded proteins in the endoplasmic reticulum (ER) triggers an
72 evolutionarily conserved intracellular signaling pathway called the unfolded protein response
73 (UPR)(1). The UPR is mainly an adaptive response to re-establish ER proteostasis through the
74 signaling of three transmembrane proteins, inositol-requiring protein 1 α (IRE1 α , hereafter
75 IRE1), protein kinase R (PKR)-like ER kinase (PERK), and activating transcription factor 6
76 (ATF6)(2). IRE1 represents the most evolutionarily conserved branch of the UPR: it is a
77 multidomain protein with an N-terminal luminal domain and cytosolic kinase and RNase
78 domains connected by a transmembrane linker(2). Upon activation, IRE1 dimerizes, trans-
79 autophosphorylates and oligomerizes, thereby activating the IRE1 RNase domain which is able
80 to remove a 26 nucleotide intron from X-Box Binding Protein 1 (XBP1) mRNA. Upon re-ligation
81 by RNA-splicing ligase RtcB, spliced XBP1 (XBP1s) is formed(2). XBP1s protein is a potent
82 transcription factor and its target genes in turn permit the ER to adapt to stress conditions(2).
83 There are several models that explain how ER stress is sensed by IRE1(3). One of the
84 established models links its trans-autophosphorylation with face-to-face dimer orientation as
85 the first step of IRE1 activation (Figure 1A), and subsequent transition to back-to-back dimer
86 (Figure 1B) and larger oligomeric structure formation to stimulate the RNase domain
87 activity(3).


88 IRE1 signaling is implicated in the etiology of various diseases(2, 4), including cancer where
89 tumor cells activate the UPR to avoid apoptosis and survive(5). Thus, IRE1 has been the recent
90 focus of several drug discovery projects in cancer research(6). Current IRE1 modulators can
91 be categorized as (i) direct IRE1 RNase inhibitors(6, 7), (ii) ATP-competitive kinase inhibitors
92 that activate RNase(8) and (iii) ATP-competitive kinase inhibitors that decrease RNase
93 activity(8, 9), the latter also known as 'kinase inhibiting RNase attenuators' (KIRAs).
94 Optimized KIRA compounds include KIRA6(10), KIRA7(4) and KIRA8(11). KIRA6 and KIRA7
95 possess an imidazopyrazine scaffold(10), whereas KIRA8 is a sulfonamide compound with high
96 selectivity(11).

97 The observation that KIRAs allosterically inhibit IRE1 RNase domain was confirmed by a
98 competitive *in-vitro* assay where ATP-competitive RNase activators were shown to completely
99 restore the RNase activity in presence of KIRA(8). The model proposed by Feldman *et al.*
100 speculates that KIRAs stabilize the DFG-out kinase domain conformation and helix- α C


101 displacement that makes it incompatible with back-to-back dimer formation, thereby leading
102 to kinase and RNase inhibition(8).

103 Herein, we propose an alternative, and we think more likely, model to rationalize the link
104 between kinase binding and RNase domain inhibition by the KIRA compounds based on
105 molecular level analyses of structures and dynamics of IRE1 in complex with KIRA
106 compound **16** (Figure 1C); numbering from the original paper(9) (hereafter referred to as
107 KIRA).

108



109



110

111 **Figure 1.** Ribbon diagram representing the structure of the IRE1 kinase and RNase of (A) the
112 face-to-face dimer (PDB 3P23) and (B) back-to-back arrangement (PDB 4YZC). The kinase
113 domain is shown in green (residues 571-832), the helix- α in red (residues 603-623), the
114 activation segment in blue (residues: 711-741) and the RNase domain in orange (residues 837-
115 963). ADP (A) and staurosporine (B) are highlighted in space-filling models to indicate the
116 kinase binding sites. (C) 2D molecular representation of KIRA.

117

118 Using protein-protein docking(12), protein-ligand docking(13) and molecular dynamics
119 (MD) simulations(13) we investigate structure and dynamics of the two relevant IRE1 dimer
120 structures (Figure 1), face-to-face and back-to-back, critical for trans-autophosphorylation
121 and RNase activity,(3) respectively. Using models in the presence and absence of KIRA
122 bound to the kinase pocket, we propose a mechanistically-based model of how KIRAs inhibit
123 the RNase activity of IRE1 by allosteric interaction with the kinase domain.

124

125 **2. Methods**


126 **2.1. Selection and preparation of IRE1 crystal structure**

127 IRE1 crystal structures with PDB codes 4U6R (KIRA-bound monomer), 3P23 (ADP bound face-
128 to-face dimer) and 4YZC (staurosporine bound back-to-back dimer) were prepared using
129 Schrödinger protein preparation wizard(14). Using the 3P23 PDB structure, the face-to-face
130 dimer was obtained by deleting Chain C and D and generating missing loops using Prime(15).
131 Hydrogen atoms were added and the protonation and tautomeric states of Asp, Glu, Arg, Lys
132 and His were adjusted to match a pH of 7.4. Possible orientations of Asn and Gln residues were
133 generated. Finally, the IRE1 dimer and monomer structures were subjected to geometry
134 refinements using the OPLS3 force field(16) in restrained minimizations.

135 **2.2. Protein-Protein Docking**

136 A protein-protein docking analysis was performed to understand the structural basis of IRE1
137 recognition and regulation mediated by KIRA. Initially, five different protein-protein docking
138 programs were chosen: SwarmDock(17), ZDOCK(18), HsymDock(19), PatchDock(20) and
139 ClusPro(21). The ability of the programs to reproduce the native IRE1 dimers (PDB code 4YZC
140 for back-to-back and 3P23 for face-to-face) was checked. The best performing program,
141 SwarmDock(17), was then used for predicting the structures of KIRA-bound dimers using the
142 4U6R PDB monomer structure. A schematic representation of the method used is shown in
143 Figure 2.

144



145

146 **Figure 2.** Schematic representation of protein-protein docking scheme used for predicting
147 KIRA-bound dimer structures.

148

149 **2.3. KIRA preparation for docking studies**

150 The co-crystallized ligand from PDB 4U6R as shown in Figure 1C was extracted from the PDB
151 structure and used for docking studies. KIRA is displayed in Figure 1C. KIRA was prepared using
152 LigPrep(22) in the Schrödinger suite(23). The OPLS3 force field(16) was used for KIRA
153 preparation steps and possible protonation and ionization states were assigned using Ionizer
154 at pH 7.4.

155 **2.4. Molecular docking of KIRA**

156 KIRA was docked in the kinase pocket of the IRE1 dimer back-to-back (PDB code: 4YZC) and
157 face-to-face (PDB code: 3P23) structures, using the Glide program(24) in Schrödinger(23) with
158 the receptor grids prepared using the OPLS3 force field(16). The molecule was docked in the
159 kinase domain of both monomers of each dimer. IRE1 dimers in apo form were obtained by

160 deleting the small organic molecules and ions present in the crystal structures, from the kinase
161 active site (*i.e.*, ADP and Mg²⁺ in the 3P23 PDB structure and staurosporine in the 4YZC PDB
162 structure, respectively). Two grid centers per dimer (*i.e.*, one per each kinase active site) were
163 prepared, each cubic grid with a side length of 20 Å. The grid center was set at the centroid of
164 Lys599, a residue crucial for the kinase activity. XP (Extra Precision) docking mode and flexible
165 ligand sampling were employed in the docking procedure. All other parameters were set to
166 default values.

167 **2.5. Molecular Dynamics Simulations**

168 The stability of the native crystallographic dimer structures of the IRE1 in back-to-back (PDB
169 4YZC) and face-to-face (PDB 3P23) conformer were compared with the predicted KIRA-bound
170 dimer forms, based on 300 ns MD simulations. For KIRA bound dimers we used both
171 complexes with KIRA docked in the kinase active site of the dimer structures 4YZC and 3P23,
172 and dimer structures generated from KIRA-co-crystallized IRE1 monomers.

173 For the MD simulations, the following steps were followed:

174 **a.** Systems preparation: Systems include the experimental IRE1 dimer structures (PDB 4YZC,
175 3P23), predicted dimers (from KIRA bound monomer) (section 2.2), and KIRA-docked dimer
176 forms (section 2.4). The systems were prepared separately as discussed in section 2.1.

177 **b.** Ligand parameterization: ligands (ADP, staurosporine and KIRA) were parametrized with
178 GAFF as implemented in Ambertools2018 by using the Antechamber interface tool(25). AM1-
179 BCC atomic point charges(26) were calculated using Antechamber(27).

180 **c.** Molecular dynamics simulation protocol: MD simulations were performed using the
181 GROMACS 5.1 package(28), with the AMBER14SB force field for the protein(29). The systems
182 were explicitly solvated using cubic water boxes with cell borders placed at least 10 Å away
183 from the protein or ligand atoms using TIP3P water(30) under periodic boundary conditions.
184 The systems were first neutralized and Na⁺/Cl⁻ counter ions were added to give a physiological
185 salt concentration of 0.154 M. All simulation runs consisted of energy minimization until the
186 force was less than 1000 kJ mol⁻¹ nm⁻¹, 200 ps under NVT conditions subjected to position
187 restrained equilibration on the heavy atoms of IRE1, 200 ps equilibration and 300 ns of
188 classical molecular dynamics simulation under NPT conditions. The simulations were run in

189 triplicate (referred to as Replica 1, 2 and 3). In all simulations, the temperature was kept at
190 300 K by the velocity rescaling thermostat(31) with a coupling constant of 0.1 ps, and pressure
191 at 1.01325 bar using the Parrinello-Rahman barostat(32) with a coupling time of 5.0 ps,
192 excluding NVT pre-simulation steps. Constraints were applied on all bonds using the LINCS
193 algorithm(33). The leap-frog algorithm(34) was employed in the simulations, with integration
194 timesteps of 2 fs.

195 The structural deviations during the MD simulation were analyzed using RMSD, number of
196 distinct hydrogen bonds and energy terms such as electrostatic (Ele) and van der Waals (vdW)
197 interactions using built-in tools in the GROMACS 5.1 package(28). For analyzing the dimer
198 interface RMSD, an index file was created with specific residues. The dimer interface was
199 defined as any pair of C α atoms from one monomer within 10 Å of the other in the face-to-
200 face and back-to-back dimers(35, 36).

201 **2.6 Data availability**

202 All simulation protocols are provided as tarballs (.tar.gz) freely accessible at zenodo.org as
203 DOI: 10.5281/zenodo.3368654.

204 There are eighteen tarball (**.tar.gz**) files, three replicas for each of the systems investigated.

205 The contents of each tarball is as follows:

- 206 1. a source PDB (**.pdb**) file
- 207 2. leap.log - commands used to create the .prmtop and .inpcrd files
- 208 3. Two AMBER parameter/topology (**.prmtop**) and an AMBER coordinate (**.inpcrd**) file
- 209 4. **.mdp file** used for performing all the minimisation, relaxation, equilibration and production
210 run steps
- 211 5. Executable **script (i.e. job009)** that was used to perform the production run
- 212 6. trajectory (**.xtc**) files for each independent MD simulations

213

214 **3. Results and discussion**

215 **3.1 Protein-Ligand Docking analysis**

216 KIRA bound IRE1 dimer crystal structures are not available. To predict the KIRA binding in
217 dimers, the compound was docked in the IRE1 back-to-back (PDB code: 4YZC) and face-to-face

218 (3P23) structures. Visual inspection of the docked poses revealed a different binding mode of
219 KIRA compared to the 4U6R PDB structure (Figure S1). In particular, in the face-to-face dimer
220 KIRA binding is mainly stabilized by electrostatic interaction with Asp711, Asp688 and Lys690
221 (Fig S2A and B) and in the back-to-back dimer with Glu651 and Cys645 (Fig S2C and D) while
222 the co-crystallized KIRA interacts mainly with Lys599, Glu651, Cys645, Phe712 and Ile642 as
223 reported in previous studies(9, 37).

224 **3.2. Protein-Protein Docking analysis**

225 To address the questions regarding the effect of KIRA binding on the IRE1 dimer formation,
226 and if KIRA is able to structurally interfere with either the face-to-face or back-to-back dimer
227 form, or both, we assessed if the KIRA-bound monomer structure (PDB code: 4U6R) is capable
228 of forming dimer structures.

229 In order to identify an appropriate protein-protein docking program, a series of docking
230 experiments were performed using five freely available programs. Starting from the known
231 crystallographic dimer structures of IRE1 in back-to-back (PDB code: 4YZC) and face-to-face
232 (3P23) conformers, we split the crystal structure into monomers and tried to reproduce the
233 dimer complexes with the programs. The docking results are shown in Table 1 and S1.

234

235 **Table 1.** RMSD^a results of five different protein–protein docking approaches to reproduce the
236 known IRE1 dimer complexes.

| | Face-to-face dimer (PDB code: 3P23) | Back-to-back dimer (PDB code: 4YZC) |
|------------------|---|--|
| SwarmDock | 1.39 | 3.56 |
| ZDOCK | 12.48 | 3.32 |
| HsymDock | 3.12 | 13.25 |
| PatchDock | 24.33 | 29.49 |
| ClusPro | 3.58 | 31.01 |


237 ^aRoot-mean-square deviation (RMSD) is calculated for C α atoms by superimposing the top-scored
238 docked pose generated by the program with the crystallographic structures.

239

240 Evaluating the RMSD over the five top-scored docked poses for all programs studied here
241 (Table S1), we note that the top-scored docking pose in almost all cases is also the one with
242 lowest RMSD. Of the five docking programs tested in the current study, SwarmDock was able
243 to reproduce the native crystallographic back-to-back (PDB code: 4YZC) and face-to-face (PDB

244 code: 3P23) dimers structures of the IRE1 to an RMSD of 3.56 and 1.39 Å, respectively, as
245 shown in Figure 3. SwarmDock was thus also used for predicting dimers of the KIRA-bound
246 monomer structures (PDB 4U6R) in the back-to-back and face-to-face orientations.

247 We first evaluated steric clashes at the interchain region by superposing the monomer of the
248 4U6R PDB structure on each monomer of the native crystallographic structures of the IRE1
249 back-to-back and face-to-face dimers (Figure S3). The KIRA-bound dimer forms produce
250 several steric clashes at interchain level, especially at the helix- α C and the activation segment
251 in KIRA-bound face-to-face dimer (Figure S3). We note that the backbone of Glu604 and the
252 carboxylate group of Glu735 create steric clashes with the guanidino group of Arg600 and the
253 carboxylate of Glu735, located in the helix- α C and the activation segment, respectively (Figure
254 S3). In the back-to-back dimer the guanidine groups of Arg627 and Arg905 create potential
255 steric clashes with the guanidine groups of Arg627 and Arg905 located in the other monomer
256 of the symmetric complex (Figure S3).




257
258 **Figure 3.** Superposition of the predicted best-scoring poses predicted by SwarmDock (green),
259 onto the crystallographic dimer structures (red) of the IRE1 in (A) face-to-face (PDB code:
260 3P23) and (B) back-to-back (PDB code: 4YZC) conformations. RMSD values based on the
261 positions of the C α atoms relative to the crystallographic structures.

262

263 Results from the protein-protein docking calculations of the KIRA-bound dimer forms
264 performed using SwarmDock are shown in Figure 4. The best docked results were analyzed
265 further through MD simulations.

266 The best docked pose (in terms of C α atom RMSD) generated for the face-to-face dimer shown
267 in Fig. 4A is very far from the experimental one, with an RMSD of 24.24 Å. No structures with
268 better RMSD were found within the 5 top scoring docking poses (RMSD 24.24, 25.29, 34.11,
269 27.49 and 25.40 Å, respectively). Since the program is shown to successfully predict the
270 crystallographic dimer forms, the high RMSD values are not likely a result of bad sampling.
271 Rather, the KIRA induced conformational changes have rendered the system incapable of
272 appropriate dimer formation.

273 Comparison of the best back-to-back docking pose obtained using the 4U6R PDB structure and
274 the crystal structures of the back-to-back dimer was also performed (Figure 4B). The RMSD
275 analysis for the best docking pose gives a value near 4 Å, in line with the RMSD value identified
276 when using the native monomer structure (Table 1).



277

278 **Figure 4.** Illustration of the protein-protein docking results of KIRA containing IRE1 monomers
279 (PDB code: 4U6R). Values shown are the RMSD in angstrom in Å of the positions of the C α
280 atoms of the best-scoring docked pose (green) against the native IRE1 dimer structure in (A)
281 face-to-face (PDB code: 3P23) and (B) back-to-back (PDB code: 4YZC) conformation (red).

282

283

284

285 3.3. MD simulations analysis: influence of KIRA on the face-to-face dimer


286 Three different IRE1 face-to-face dimers were explored further, namely the native crystal
287 dimer structure (PDB code: 3P23), the native structure (PDB 3P23) with KIRA docked in the
288 active sites, and the protein-protein docked pose of PDB 4U6R in the face-to-face dimer. The

289 stability of each of the three systems was analyzed during three MD replicas, each replica
290 being 300 ns duration.


291 To assess the structural stabilities, RMSD values of each dimer and of the dimer interfaces
292 were calculated (Figure 5). For each replica, the calculations were done by considering the
293 structures present in the minimized, equilibrated systems as the reference points. RMSD
294 values were analyzed as the functions of simulation time. The three replicas for the native
295 face-to-face crystal dimer (PDB code: 3P23) reveal that the IRE1 dimer is stable as evidenced
296 by low and relatively constant RMSD values of the three independent trajectories (Figures 5A
297 and D). In contrast, the KIRA-docked face-to-face dimer and the predicted PDB 4U6R dimer
298 reach higher values of RMSD (Figures 5B, C, D and E) indicating that these dimers explore more
299 distorted complexes compared to the native IRE1 face-to-face dimer. Conformations with
300 large interface RMSD were visually examined and by comparing the distance of the center of
301 mass (COM) of each RNase domain in each dimer with the native face-to-face dimer we
302 analyze the impact of KIRA on the stability of the system (Figure S4). The COM distance of the
303 RNase domain in the KIRA docked in PDB 3P23 dimer and in the protein-protein docked pose
304 of PDB 4U6R in face-to-face dimer form are significantly higher compared to native IRE1 dimer
305 demonstrating the impact of KIRA on the stability of the system (Figure S4).

306

307



308



309 **Figure 5.** RMSDs of IRE1 face-to-face dimer C α atoms during the three MD simulation replicas
310 of (A) Native face-to-face crystal dimer structure (PDB code: 3P23), (B) KIRA docked in PDB
311 3P23 dimer, (C) protein-protein docked pose of PDB 4U6R in face-to-face dimer form.
312 Interface RMSDs of IRE1 face-to-face dimer C α atoms during the three MD simulation replicas
313 of (D) Native face-to-face crystal dimer structure (PDB code: 3P23), (E) KIRA docked in PDB
314 3P23 dimer, (F) protein-protein docked pose of PDB 4U6R in face-to-face dimer form. Replicas
315 1, 2, and 3 are represented in red, green and blue, respectively. Individual frames of the MD
316 simulations labeled a, b and c are shown in Figure S4.

317

318 To further analyze the system deviation, the interaction energy and the number of H-bonds
319 between the monomers were computed (Figure 6). Interaction energy analysis between the
320 monomers reveals a smaller energetic stabilization of the KIRA-docked face-to-face dimer and
321 the protein-protein docked pose of PDB 4U6R in face-to-face dimer form, compared to the
322 native face-to-face crystal dimer (PDB code: 3P23) (Figure 6). The same trend was confirmed
323 by the H-bonds analysis, with a higher number of H-bonds occurring between the native IRE1
324 face-to-face dimer compared to protein-protein docked pose and KIRA-docked face-to-face
325 dimer (Figure 6). The overall analysis confirms our initial interpretation of the different
326 stabilities of the three IRE1 face-to-face dimers investigated, with the native one being the
327 more stable, indirectly reflecting the impact of KIRA on the stabilization of the IRE1 face-to-
328 face dimer.


329 Moreover, energetic analysis of KIRA and ADP in each kinase active site of the face-to-face
330 dimer revealed a lower energetic stabilization of ADP compared to KIRA, with each ligand
331 being able to interact favorably with the IRE1 active site pocket for the entire simulation time
332 during all three replicas (Figure S5).

333 **3.4. MD simulations analysis: influence of KIRA on the back-to-back dimer**


334 To investigate impact of KIRA on the IRE1 back-to-back dimer, three different systems were
335 also considered here, namely the native back-to-back dimer crystal structure (PDB code:
336 4YZC), the native dimer structure (PDB code: 4YZC) with KIRA docked, and the protein-protein
337 docked pose of PDB 4U6R in back-to-back dimer form, respectively. The stabilities of the three
338 systems were studied during three MD replicas, each replica being 300 ns in length.

339


340




341



342



343




344

345 **Figure 6.** IRE1 face-to-face dimer MD simulations. Time-dependent interaction energy profiles
346 for monomer A with monomer B during the three MD simulation replicas of (A) Native face-
347 to-face crystal dimer (PDB code: 3P23), (B) KIRA-docked face-to-face dimer (PDB code: 3P23),
348 (C) protein-protein docked pose of PDB 4U6R in face-to-face dimer form. Hydrogen bond
349 analysis between monomers A and B during three MD replicas for (D) Native face-to-face
350 crystal dimer (PDB code: 3P23), (E) KIRA-docked face-to-face dimer (PDB code: 3P23), (F)
351 protein-protein docked pose of PDB 4U6R in face-to-face dimer form.

352

353 As reported in section 3.2 to assess the structural stability of the dimer structures, RMSD
354 values of each dimer and the RMSD for the IRE1 dimer interface (Figure 7 and S6, respectively)
355 were calculated. For each replica the structure present in the minimized, equilibrated system
356 was used as the reference point and RMSD values were analyzed as functions of simulation
357 time. The three replicas for the native back-to-back crystal dimer (PDB code: 4YZC) revealed
358 that the IRE1 dimer is stable, as evidenced by low and relatively constant RMSD values of the
359 three independent trajectories (Figure 7A and S6A). In contrast to the face-to-face dimer
360 systems investigated, the KIRA-docked back-to-back dimer (PDB code: 4YZC) and the protein-
361 protein docked pose of PDB 4U6R in the back-to-back dimer form show similar structural
362 stabilities as the native IRE1 back-to-back dimer (Figures 7B, C and S6B and C).




364 **Figure 7.** RMSDs of IRE1 back-to-back dimer C α atoms during three MD replicas for (A) Native
365 back-to-back dimer from crystal structure (PDB code: 4YZC), (B) KIRA docked in PDB 4YZC
366 structure and (C) protein-protein docked pose of PDB 4U6R in back-to-back dimer form. Red
367 for Replica 1, green for Replica 2 and blue for Replica 3, respectively.


368

369 Also for the three back-to-back systems, the interaction energy and the number of H-bonds
370 between the monomers were analyzed (Figure 8). Energetic analysis of the occurring
371 interchain interactions shows similar energetic stabilization of all three back-to-back dimers
372 structures, and in all three replicas (Figure 8). The same trend was confirmed by the H-bonds
373 analysis, with an equal number of H-bonds occurring between the native IRE1 back-to-back
374 dimer compared to protein-protein docked pose and KIRA-docked back-to-back dimer (Figure
375 8). The overall analysis of these three IRE back-to-back dimers confirms our initial
376 interpretation of the similar stabilities of the three dimer models. To further validate this
377 hypothesis the last frame of each MD simulations were superposed with the native back-to-
378 back dimer revealing an overall similar IRE1 back-to-back active conformation (Figure S7).


379




380



381



382



383 **Figure 8.** IRE1 back-to-back dimer MD simulation data for the three MD replicas. Time-
384 dependent interaction energy profiles for monomer A with monomer B during the MD
385 simulations of (A) native back-to-back dimer (PDB code: 4YZC), (B) KIRA docked in the 4YZC
386 structure, (C) protein-protein docked pose of PDB 4U6R in back-to-back dimer. Hydrogen bond
387 analysis between the monomers A and B during the three MD replicas for (D) native back-to-
388 back crystal dimer (PDB code: 4YZC), (E) KIRA docked in PDB 4YZC structure, (F) protein-protein
389 docked pose of PDB 4U6R in back-to-back dimer form.

390

391

392 Moreover, energetic analysis of KIRA and staurosporine in each kinase active site of the back-
393 to-back dimer revealed similar energetic stabilization of staurosporine compared to KIRA, with
394 each ligand being able to interact favorable with the IRE1 pocket active site during the entire
395 simulation in the three replicas (Figure S8).

396

397 **4. Conclusions and perspective**

398 We have investigated the impact of KIRA binding on IRE1 dimer structures. Unexpectedly, the
399 docking and MD simulations studies reveal that KIRA can bind to the kinase pocket of IRE1 in
400 both the native face-to-face and back-to-back forms. A detailed analysis of the IRE1 monomer-
401 monomer interactions process for the face-to-face dimer in presence of KIRA revealed
402 energetic destabilization, suggesting that the binding of KIRA is affecting the system already
403 at the stage of face-to-face dimer formation. Given that IRE1 activation appears to be
404 dependent on the close communication between the kinase and RNase domains, the data
405 leads us to believe that KIRA has a prominent role at the early stage of IRE1 activation, by
406 destabilizing face-to-face dimer formation. This will impair the trans-autophosphorylation
407 process, and thus preventing IRE1 from reaching the RNase active back-to-back structure.

408 The proposed mechanism of blocking the trans-autophosphorylation provides a molecular
409 level validation of available experimental data where KIRA compounds inhibit IRE1
410 phosphorylation(8). This is further supported by the experimental observation that upon the
411 inclusion of KIRAs, Western blotting reveals formation of IRE1 monomers only(8).

412 The data reported herein provide another small piece of information towards the
413 understanding of IRE1 activity and the structural evidence of KIRA's role in the IRE1 inhibition
414 process, representing a stimulus to explore and better understand the IRE1 signaling.

415

416 **Acknowledgements**

417 This research was funded by the EU's Horizon 2020 research and innovation programme under
418 the Marie Skłodowska-Curie grant 675448 (TRAINERS). The Faculty of Science at the University
419 of Gothenburg and the Swedish Science Research Council (VR; grant number 2014-3914) are
420 gratefully acknowledged for financial support (LAE) and the Swedish National Infrastructure
421 for Computing for allocations of computing time at supercomputing centers C3SE and PDC.

422

423 **Conflicting Interests**

424 AG, AS and LE are cofounders of Cell Stress Discoveries, Ltd. No conflicting interests.

425

426 **Supplementary material**

427 RMSD data of top 5 docked poses (Table S1), Superposed structures displaying steric clashes
428 (Figure S1), RMSDs of interface region in back-to-back dimers (Figure S2), and Structures at
429 the three time points indicated in Figures 5D-F (Figure S3), are available as Supplementary
430 material.

431

432 **Author Information**

433 Corresponding Author:

434 *E-mail: leif.eriksson@chem.gu.se.

435

436 Author contributions:

437 All authors conceived the study. AC and CC performed the computations, analysed the data
438 and wrote first draft. All authors revised the text.

439

440 **Bibliography**

- 441 1. D. Ron, P. Walter, Signal integration in the endoplasmic reticulum unfolded protein
442 response. *Nat Rev Mol Cell Biol* **8**, 519-529 (2007).
- 443 2. A. Almanza *et al.*, Endoplasmic reticulum stress signalling - from basic mechanisms to
444 clinical applications. *FEBS J* **286**, 241-278 (2019).
- 445 3. C. J. Adams, M. C. Kopp, N. Larburu, P. R. Nowak, M. M. U. Ali, Structure and Molecular
446 Mechanism of ER Stress Signaling by the Unfolded Protein Response Signal Activator
447 IRE1. *Front Mol Biosci* **6**, 11 (2019).
- 448 4. M. Thamsen *et al.*, Small molecule inhibition of IRE1alpha kinase/RNase has anti-fibrotic
449 effects in the lung. *PLoS One* **14**, e0209824 (2019).
- 450 5. W. A. Wang, J. Groenendyk, M. Michalak, Endoplasmic reticulum stress associated
451 responses in cancer. *Biochim Biophys Acta* **1843**, 2143-2149 (2014).
- 452 6. D. J. Maly, F. R. Papa, Druggable sensors of the unfolded protein response. *Nat Chem*
453 *Biol* **10**, 892-901 (2014).
- 454 7. M. Sanches *et al.*, Structure and mechanism of action of the hydroxy-aryl-aldehyde class
455 of IRE1 endoribonuclease inhibitors. *Nat Commun* **5**, 4202 (2014).
- 456 8. H. C. Feldman *et al.*, Structural and Functional Analysis of the Allosteric Inhibition of
457 IRE1alpha with ATP-Competitive Ligands. *ACS Chem Biol* **11**, 2195-2205 (2016).
- 458 9. P. E. Harrington *et al.*, Unfolded Protein Response in Cancer: IRE1alpha Inhibition by
459 Selective Kinase Ligands Does Not Impair Tumor Cell Viability. *Acs Med Chem Lett* **6**, 68-

- 460 72 (2015).
- 461 10. R. Ghosh *et al.*, Allosteric inhibition of the IRE1alpha RNase preserves cell viability and
462 function during endoplasmic reticulum stress. *Cell* **158**, 534-548 (2014).
- 463 11. S. Morita *et al.*, Targeting ABL-IRE1alpha Signaling Spares ER-Stressed Pancreatic beta
464 Cells to Reverse Autoimmune Diabetes. *Cell Metab* **25**, 1207 (2017).
- 465 12. K. A. Porter, I. Desta, D. Kozakov, S. Vajda., What method to use for protein-protein
466 docking? *Curr Opin Struct Biol* **55**, 1-7 (2019).
- 467 13. V. Salmaso, S. Moro, Bridging Molecular Docking to Molecular Dynamics in Exploring
468 Ligand-Protein Recognition Process: An Overview. *Front Pharmacol* **9**, 923 (2018).
- 469 14. G. M. Sastry, M. Adzhigirey, T. Day, R. Annabhimoju, W. Sherman, Protein and ligand
470 preparation: parameters, protocols, and influence on virtual screening enrichments. *J*
471 *Comput Aided Mol Des* **27**, 221-234 (2013).
- 472 15. M. P. Jacobson *et al.*, A hierarchical approach to all-atom protein loop prediction.
473 *Proteins* **55**, 351-367 (2004).
- 474 16. E. Harder *et al.*, OPLS3: A Force Field Providing Broad Coverage of Drug-like Small
475 Molecules and Proteins. *J Chem Theory Comput* **12**, 281-296 (2016).
- 476 17. M. Torchala, I. H. Moal, R. A. Chaleil, J. Fernandez-Recio, P. A. Bates, SwarmDock: a
477 server for flexible protein-protein docking. *Bioinformatics* **29**, 807-809 (2013).
- 478 18. B. G. Pierce *et al.*, ZDOCK server: interactive docking prediction of protein-protein
479 complexes and symmetric multimers. *Bioinformatics* **30**, 1771-1773 (2014).
- 480 19. Y. Yan, H. Tao, S. Y. Huang, HSYMDOCK: a docking web server for predicting the
481 structure of protein homo-oligomers with Cn or Dn symmetry. *Nucleic Acids Res* **46**,
482 W423-W431 (2018).
- 483 20. D. Schneidman-Duhovny, Y. Inbar, R. Nussinov, H. J. Wolfson, PatchDock and
484 SymmDock: servers for rigid and symmetric docking. *Nucleic Acids Res* **33**, W363-367
485 (2005).
- 486 21. D. Kozakov *et al.*, The ClusPro web server for protein-protein docking. *Nat Protoc* **12**,
487 255-278 (2017).
- 488 22. Schrödinger Release 2017-1: LigPrep, Schrödinger, LLC, New York, NY, 2017.
- 489 23. Schrödinger Release 2017-1: Maestro, Schrödinger, LLC, New York, NY, 2017.
- 490 24. R. A. Friesner *et al.*, Extra precision glide: docking and scoring incorporating a model of
491 hydrophobic enclosure for protein-ligand complexes. *J Med Chem* **49**, 6177-6196
492 (2006).
- 493 25. J. Wang, R. M. Wolf, J. W. Caldwell, P. A. Kollman, D. A. Case, Development and testing
494 of a general amber force field. *J Comput Chem* **25**, 1157-1174 (2004).
- 495 26. A. Jakalian, D. B. Jack, C. I. Bayly, Fast, efficient generation of high-quality atomic
496 charges. AM1-BCC model: II. Parameterization and validation. *J Comput Chem* **23**, 1623-
497 1641 (2002).
- 498 27. Gaussian 09, Revision B.01, M. J. Frisch *et al.* Gaussian, Inc., Wallingford CT, 2016.
- 499 28. M. James, *et al.*, GROMACS: High performance molecular simulations through multi-
500 level parallelism from laptops to supercomputers. *SoftwareX* **2**, 19-25 (2015).
- 501 29. J. A. Maier *et al.*, ff14SB: Improving the Accuracy of Protein Side Chain and Backbone
502 Parameters from ff99SB. *J Chem Theory Comput* **11**, 3696-3713 (2015).
- 503 30. P. Mark, L. Nilsson, Structure and dynamics of the TIP3P, SPC, and SPC/E water models
504 at 298 K. *J Phys Chem B* **105**, 24a-24a (2001).
- 505 31. G. Bussi, T. Zykova-Timan, M. Parrinello, Isothermal-isobaric molecular dynamics using
506 stochastic velocity rescaling. *J Chem Phys* **130** (2009).

- 507 32. M. Parrinello, A. Rahman, Polymorphic transitions in single crystals: A new molecular
508 dynamics method. *J Appl Phys* **52**, 7182-7190 (1981).
- 509 33. B. Hess, H. Bekker, H. J. C. Berendsen, J. G. E. M. Fraaije, LINCS: A linear constraint solver
510 for molecular simulations. *J Comput Chem* **18**, 1463-1472 (1997).
- 511 34. W. F. Van Gunsteren, H. J. C. Berendsen, A Leap-Frog Algorithm for Stochastic Dynamics.
512 *Mol Simulat* **1**, 173-185 (1988).
- 513 35. Q. Wang, Y. Pechersky, S. Sagawa, A. C. Pan, D. E. Shaw, Structural mechanism for
514 Bruton's tyrosine kinase activation at the cell membrane. *Proc Natl Acad Sci U S A* **116**,
515 9390-9399 (2019).
- 516 36. A. C. Pan *et al.*, Atomic-level characterization of protein-protein association. *Proc Natl*
517 *Acad Sci U S A* 10.1073/pnas.1815431116 (2019).
- 518 37. A. Carlesso, C. Chintha, A. M. Gorman, A. Samali, L. A. Eriksson, Binding Analysis of the
519 Inositol-Requiring Enzyme 1 Kinase Domain. *Acs Omega* **3**, 13313-13322 (2018).

Structural distortions induced by Kinase Inhibiting RNase Attenuator (KIRA) compounds prevent the formation of face-to-face dimers of Inositol Requiring Enzyme 1 α .

Antonio Carlesso^{1‡}, Chetan Chintha^{2‡}, Adrienne M. Gorman², Afshin Samali² and Leif A. Eriksson^{1*}

¹Department of Chemistry and Molecular Biology, University of Gothenburg, 405 30 Göteborg, Sweden

²Apoptosis Research Centre, National University of Ireland Galway, Galway, Ireland.

[‡]Equal contribution

*Correspondence

Leif A. Eriksson, Department of Chemistry and Molecular Biology,
University of Gothenburg, 405 30 Göteborg, Sweden.
Email: leif.eriksson@chem.gu.se

SUPPLEMENTARY INFORMATION

| | Page |
|---|------|
| Table S1. RMSD for the 5 top-scored docked poses generated using five different protein–protein docking approaches to reproduce the known IRE1 dimer complexes. | S3 |
| Figure S1. Representation of the KIRA docking pose in (A) Chain A of 3P23 PDB code, (B) Chain B of 3P23 PDB code, (C) Chain A of 4YZC PDB code, (D) Chain B of 4YZC PDB code. The crystallographic pose of KIRA in the 4U6R PDB structure is shown in panel E. | S4-5 |
| Figure S2. 2D representation diagrams of the KIRA binding modes in (A) Chain A of 3P23 PDB code, (B) Chain B of 3P23 PDB code, (C) Chain A of 4YZC PDB code, and (D) Chain B of 4YZC PDB code. | S6-8 |
| Figure S3. Ribbon diagram representing the structure of the KIRA-bound dimer forms obtained by superposition of the monomer of the 4U6R PDB structure on each monomer of the native | |

crystallographic structures of the IRE1 in (A) face-to-face (PDB 3P23) and (B) back-to-back (PDB code: 4YZC) dimers. The kinase domain is shown in green (residues 571-832), the helix- α C in red (residues 603-623), the activation segment in blue (residues: 711-741) and the RNase domain in orange (residues 837-963). Violet spheres = steric clashes. S9-10

Figure S4. Comparison of the (A) native face-to-face crystal dimer structure (PDB code: 3P23) (point 'a' in Panel D of Figure 5), with the higher interface RMSD frame identified from three independent MD replicas for (B) KIRA docked in PDB 3P23 dimer (point 'b' in Panel E of Figure 5) and (C) protein-protein docked pose of PDB 4U6R in face-to-face dimer (point 'c' in Panel F of Figure 5). The distance between the RNase domain Center of Mass (COM) of dimer is shown. The kinase domain is shown in green (residues 571-832), the helix- α C in red (residues 603-623), the activation segment in blue (residues: 711-741) and the RNase domain in orange (residues 837-963). ADP (A) and KIRA (B) highlighted in space-filling model to indicate the kinase binding site. S11-12

Figure S5. IRE1 face-to-face dimer MD simulations. Time-resolved interaction energy profiles for ADP during the three MD simulation replicas of the native face-to-face crystal dimer (PDB code: 3P23): (A) Chain A, (B) Chain B. Time-resolved interaction energy profiles during the three MD simulation replicas for KIRA docked in the native face-to-face crystal dimer (PDB code: 3P23): (C) Chain A and (D) Chain B. S13

Figure S6. Interface RMSDs of IRE1 back-to-back dimer C α atoms during the three MD simulation replicas of (A) native back-to-back crystal dimer structure (PDB code: 4YZC), (B) KIRA docked in PDB 4YZC dimer, and (C) protein-protein docked pose of PDB 4U6R in back-to-back dimer form. Replicates 1, 2, and 3 are represented in red, green and blue, respectively. S14

Figure S7. Superposition of the last frame of each individual MD simulation (green) of (A) native back-to-back dimer from crystal structure (PDB code: 4YZC), (B) KIRA docked in PDB 4YZC structure and (C) protein-protein docked pose of PDB 4U6R in back-to-back dimer, onto the native back-to-back crystallographic structure (PDB code: 4YZC) (red). S15

Figure S8. IRE1 back-to-back dimer MD simulations. Time-resolved interaction energy profiles for staurosporine during the three MD simulation replicas of the native back-to-back crystal dimer (PDB code: 4YZC): (A) Chain A, (B) Chain B. Time-resolved interaction energy profiles during the three MD simulation replicas for KIRA docked in the native back-to-back crystal dimer (PDB code: 4YZC): (C) Chain A and (D) Chain B. S16-17

Table S1. RMSD^a for the 5 top-scored docked poses generated using five different protein–protein docking approaches to reproduce the known IRE1 dimer complexes.

| | Face-to-face dimer (PDB code: 3P23) | Back-to-back dimer (PDB code: 4YZC) |
|------------------|---|--|
| SwarmDock | 1.39, 27.47, 12.94, 16.43, 1,42 | 3.56, 31.58, 23.99, 20.23, 34.32 |
| ZDOCK | 12.48, 14.59, 0.97, 16.24, 3.65 | 3.32, 23.70, 31.57, 33.97, 13.34 |
| HsymDock | 3.12, 33.20, 39.72, 38.63, 33.62 | 13.25, 12.84, 30.68, 28.96, 35.72 |
| PatchDock | 24.33, 30.03, 25.45, 28.00, 32,59 | 29.49, 21.59, 28.19, 25.35, 21.79 |
| ClusPro | 3.58, 11.91, 22.40, 17.65, 29.22 | 31.01, 33.02, 30.02, 34.60, 30.10 |

^aRoot-mean-square deviation (RMSD) is calculated for C α atoms by superimposing the five top-scored docked poses generated by the programs, with the crystallographic structures.







Figure S1. Representation of the KIRA docking pose in (A) Chain A of 3P23 PDB code, (B) Chain B of 3P23 PDB code, (C) Chain A of 4YZC PDB code, (D) Chain B of 4YZC PDB code. The crystallographic pose of KIRA in the 4U6R PDB structure is shown in panel E.

A**B**

C



D





Figure S2. 2D representation diagrams of the KIRA binding modes in (A) Chain A of 3P23 PDB code, (B) Chain B of 3P23 PDB code, (C) Chain A of 4YZC PDB code, and (D) Chain B of 4YZC PDB code.

A






B

Figure S3. Ribbon diagram representing the structure of the KIRA-bound dimer forms obtained by superposition of the monomer of the 4U6R PDB structure on each monomer of the native crystallographic structures of the IRE1 in (A) face-to-face (PDB 3P23) and (B) back-to-back (PDB code: 4YZC) dimers. The kinase domain is shown in green (residues 571-832), the helix- α C in red (residues 603-623), the activation segment in blue (residues: 711-741) and the RNase domain in orange (residues 837-963). Violet spheres = steric clashes.



C




Figure S4. Comparison of the (A) native face-to-face crystal dimer structure (PDB code: 3P23) (point 'a' in Panel D of Figure 5), with the higher interface RMSD frame identified from three independent MD replicas for (B) KIRA docked in PDB 3P23 dimer (point 'b' in Panel E of Figure 5) and (C) protein-protein docked pose of PDB 4U6R in face-to-face dimer (point 'c' in Panel F of Figure 5). The distance between the RNase domain Center of Mass (COM) of dimer is shown. The kinase domain is shown in green (residues 571-832), the helix- α C in red (residues 603-623), the activation segment in blue (residues: 711-741) and the RNase domain in orange (residues 837-963). ADP (A) and KIRA (B) highlighted in space-filling model to indicate the kinase binding site.




Figure S5. IRE1 face-to-face dimer MD simulations. Time-resolved interaction energy profiles for ADP during the three MD simulation replicas of the native face-to-face crystal dimer (PDB code: 3P23): (A) Chain A, (B) Chain B. Time-resolved interaction energy profiles during the three MD simulation replicas for KIRA docked in the native face-to-face crystal dimer (PDB code: 3P23): (C) Chain A and (D) Chain B.




Figure S6. Interface RMSDs of IRE1 back-to-back dimer C α atoms during the three MD simulation replicas of (A) native back-to-back crystal dimer structure (PDB code: 4YZC), (B) KIRA docked in PDB 4YZC dimer, and (C) protein-protein docked pose of PDB 4U6R in back-to-back dimer form. Replicates 1, 2, and 3 are represented in red, green and blue, respectively.




Figure S7. Superposition of the last frame of each individual MD simulation (green) of (A) native back-to-back dimer from crystal structure (PDB code: 4YZC), (B) KIRA docked in PDB 4YZC structure and (C) protein-protein docked pose of PDB 4U6R in back-to-back dimer, onto the native back-to-back crystallographic structure (PDB code: 4YZC) (red).




Figure S8. IRE1 back-to-back dimer MD simulations. Time-resolved interaction energy profiles for staurosporine during the three MD simulation replicas of the native back-to-back crystal dimer (PDB code: 4YZC): (A) Chain A, (B) Chain B. Time-resolved interaction energy profiles during the

three MD simulation replicas for KIRA docked in the native back-to-back crystal dimer (PDB code: 4YZC): (C) Chain A and (D) Chain B.